Terms ending in 2034
Every in-force patent on Astellas US LLC's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,808,530 | Composition of Tiacumicin Compounds In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,273,171 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | Astellas US LLC | In force | High confidence | |
| US 11,491,176 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | Astellas US LLC | In force | High confidence | |
| US 12,016,875 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | Astellas US LLC | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Astellas US LLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.